Electrokinetic paper diagnostic platform: 15-minute, quantitative nucleic acid amplification for viral pathogens in whole blood

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $413,677
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    JONATHAN D POSNER
  • Research Location

    United States of America
  • Lead Research Institution

    UNIVERSITY OF WASHINGTON
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

ABSTRACTCOVID-19 is a severe respiratory tract infection caused by the newly discovered, and highly contagious, SARS-CoV-2 virus that emerged in late 2019 in Wuhan, China and has infected over 3 million people globally (> 1MUS) and has caused over 215,000 deaths (58,000 US). SARS-CoV-2 RNA is the only sensitive and specificbiomarker for diagnosis of an active COVID-19 infection and is diagnosed by reverse-transcription polymerasechain reaction (RT-PCR) in a central virology lab. Several CLIA-waived NAAT systems have been rapidlyadapted for testing COVID-19, and have been granted the Emergency Use Authorization (EUA) for use at thepoint-of-care; however, their use is generally restricted to clinical sites because of the instrument, and/or protocolcomplexity, and high cost associated with the equipment. Self-administered nasal swabs have been shown tobe an effective sample to detect COVID-19, and as a result the FDA is allowing their use as an acceptablespecimen for COVID-19 laboratory testing, paving the way for home-based COVID NAT tests.We currently have a NIBIB project focused on the development and validation of a paper microfluidic based POCNAT for quantifying HIV Viral load from whole blood. Here, we propose to leverage this on-going effort to developa COVID-19 Nucleic Acid Amplification Self Test (COAST) that can be performed at home to detect COVID-19infections based on SARS-CoV-2 RNA. COAST is fully disposable test will detect as little as 5,000 cp/swab,have a COGS of less than $2.50, and will have sample-to-result within 30 minutes. In this proposal, our primaryobjectives are (1) optimizing and validating a sensitive and specific Recombinase Polymerase Amplification(RPA) isothermal amplification assay for the N-gene for SARS-CoV-2 RNA with lateral flow readout and (2)developing and evaluating the COAST home-based test with integrated sample preparation, isothermalamplification, lateral flow read-out. RPA is a low-temperature, isothermal amplification chemistry that canspecifically detect a target with a wide range of genomic diversity and easily be integrated with LFA read-out.COAST has a novel elution tube, self-regulating positive temperature coefficient heaters, on-paper RPAamplification, and LFA readout. The RPA assay will be validated with de-identified SARS-CoV-2 RNA fromCOVID-19 patient samples collected by UWs Virology Lab and the COAST cartridge will be evaluated usingmock nasal swabs with non-infectious targets.COVID-19 self-testing can drastically increase total testing numbers which can improve state and federal publichealth officials understanding of disease proliferation, as well as informing policy response (e.g. stay-at-homeorders, school closures, etc.) and allocation of emergency response (for example distribution of PPE orventilators). Self-testing can also reduce new infections by initiating prompt quarantine and public health contacttracing, especially in the case of asymptomatic or mildly symptomatic patients.